LINDSAY COLEMAN: Open Payments
NPI 1205575727 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,499 in 138 payments from 28 companies in 2025. Trend: 2023 $2,974 · 2024 $2,862 · 2025 $2,499
Food & beverage: $2,499
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 30 | $444 |
| ABBVIE INC. | 22 | $387 |
| Otsuka America Pharmaceutical, Inc. | 17 | $244 |
| AstraZeneca Pharmaceuticals LP | 4 | $167 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $147 |
| Novartis Pharmaceuticals Corporation | 4 | $103 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $88 |
| Astellas Pharma US Inc | 4 | $85 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Phathom Pharmaceuticals, Inc. | 4 | $79 |
Products named: NURTEC ODT, REXULTI, VRAYLAR, UBRELVY, CAPLYTA, AIRSUPRA, LEQVIO, Kerendia.
Industry payments across KY — which companies pay providers there.
